China Has Led Global In Vivo CAR-T Therapy Trials
The FDA approved a Chinese-developed therapy for US trials, signaling a shift in the global CAR-T research landscape.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you trust that international collaboration on medical research will lead to better treatment outcomes?
China now accounts for 82% of the 140 in vivo CAR-T-cell drugs currently under development worldwide. This dominance in research has moved to the US stage, following the FDA's September 2026 approval of a China-developed CAR-T therapy for domestic clinical trials.
Why it matters
China has accelerated development by utilizing investigator-initiated trials and strong institutional support to address a large domestic patient population. This growth creates a new international pipeline for therapies that instruct the body to modify its own immune cells.
Researchers have reported symptom improvement in 16 patients with autoimmune diseases, including five individuals with treatment-resistant lupus. These results were observed three months after administration of the in vivo CAR-T-cell therapy.
The players
US Food and Drug Administration
The federal agency responsible for regulating clinical trial safety and therapeutic efficacy in the United States.
The details
In vivo CAR-T-cell therapy involves instructing the body to modify its own immune cells to identify and attack diseased cells without the need for extensive laboratory cell processing. Researchers in China frequently utilize investigator-initiated trials—clinical studies conducted by academic or medical staff without commercial regulatory oversight—to accelerate the testing of these therapies in human subjects. This methodology allows for rapid data collection on the efficacy of instructing the immune system to mitigate autoimmune responses.
Timeline
September 2025: Initial in-human trials for autoimmune disease reported results.
August 2026: An analysis report on global CAR-T clinical trials was published.
September 2026: The FDA approved the first China-developed therapy for US trials.
The Tech Race
The transition to in vivo CAR-T therapies marks a departure from the manufacturing-heavy precedent set by traditional ex vivo cell production standards. This shift aims to reduce complexity and cost by eliminating the need to process cells outside the body.
Patients may see expanded access to these experimental therapies as they transition from investigator-initiated trials in China to supervised clinical trials in the United States. Future availability depends entirely on developers producing long-term data that meets international regulatory standards.
The takeaway
The field is moving from small-scale academic trials to international clinical programs that seek to validate the efficacy of in vivo CAR-T interventions. Observers should watch for new safety and efficacy data from the FDA-approved US trials, which will determine the commercial viability of these treatments.
Further reading
For more on the current state of genetic medicine and cellular engineering, visit Biotech.
Live Poll
Do you trust that international collaboration on medical research will lead to better treatment outcomes?
